Eyenovia
Eyenovia
EYEN
NASDAQ
1.57
USD
-4.85%
About
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery.
Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching.
MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 5.1M |
| Three Month Average Volume | 34.0M |
| High Low | |
| Fifty-Two Week High | 2.57 USD |
| Fifty-Two Week Low | 0.37 USD |
| Fifty-Two Week High Date | 04 Mar 2024 |
| Fifty-Two Week Low Date | 21 Aug 2024 |
| Price and Volume | |
| Current Price | 0.5501 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -51.34% |
| Thirteen Week Relative Price Change | -36.39% |
| Twenty-Six Week Relative Price Change | -78.89% |
| Fifty-Two Week Relative Price Change | -76.77% |
| Year-to-Date Relative Price Change | -77.67% |
| Price Change | |
| One Day Price Change | 2.78% |
| Thirteen Week Price Change | -31.92% |
| Twenty-Six Week Price Change | -76.79% |
| Five Day Price Change | -5.48% |
| Fifty-Two Week Price Change | -70.89% |
| Year-to-Date Price Change | -73.55% |
| Month-to-Date Price Change | -55.99% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.19755 USD |
| Book Value Per Share (Most Recent Quarter) | -0.04246 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.15095 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.15215 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.73926 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 9.0E-5 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00067 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.66437 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.78973 USD |
| Normalized (Last Fiscal Year) | -0.66437 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.66437 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.78973 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.66437 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.78973 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.32597 USD |
| Cash Per Share (Most Recent Quarter) | 0.04122 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.64528 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.76772 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.66092 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -630 |
| Cash Flow Revenue (Trailing Twelve Months) | -99,059 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -118,693.60% |
| Pretax Margin (Last Fiscal Year) | -719,290.30% |
| Pretax Margin (5 Year) | -680.95% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 0.00% |
| Gross Margin (Trailing Twelve Months) | -1,489.11% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -670,354.60% |
| Operating Margin (Trailing Twelve Months) | -114,428.20% |
| Operating Margin (5 Year) | -661.44% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -719,290.30% |
| Net Profit Margin (Trailing Twelve Months) | -118,693.60% |
| Net Profit Margin (5 Year) | -680.95% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -33.07% |
| Tangible Book Value (5 Year) | -16.44% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -87.63% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 152.20% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -27.52% |
| EPS Change (Trailing Twelve Months) | -13.39% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 11.8M |
| Net Debt (Last Fiscal Year) | -562,410 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11.2K |
| Price to Sales (Trailing Twelve Months) | 1.3K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 100 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | 0 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -26,684,130 |
| Free Cash Flow (Trailing Twelve Months) | -31,114,530 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -15 |
| Net Interest Coverage (Trailing Twelve Months) | -41 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 159 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -91.15% |
| Return on Assets (Trailing Twelve Months) | -154.24% |
| Return on Assets (5 Year) | -80.31% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -207.83% |
| Return on Equity (Trailing Twelve Months) | -914.66% |
| Return on Equity (5 Year) | -140.29% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -119.11% |
| Return on Investment (Trailing Twelve Months) | -262.28% |
| Return on Investment (5 Year) | -117.70% |